Synaptics TouchView TDDI Portfolio Expands with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Synaptics TouchView TDDI Portfolio Expands with Feature-Rich TD4303 Solution

TOKYO and SAN JOSE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Synaptics Incorporated (NASDAQ: SYNA ), the leading developer of human interface solutions, today announced expansion of its touch controller and display driver integration (TDDI) product portfolio with its new TD4303 hybrid in-cell solution. Synaptics TouchView ™ TDDI technology marked an inflection point for a new era in smartphone architectures and is today shipping in mass production volumes -- with many of the world’s top brands now releasing TDDI-based models to the market.

The TouchView TD4303 further expands Synaptics’ ability to address this fast growing TDDI-based smartphone market with its first-in-the-industry support for hybrid in-cell panel technology. TD4303 supports Full HD resolution and includes integrated RAM which provides lower power and enables an extended feature-set – ideal for mainstream LTPS-based smartphones.

“Our first-to-market leadership in TDDI technology has garnered terrific traction and we are today shipping significant volumes of these solutions,” said Kevin Barber, senior vice president, general manager, Smart Display Division, Synaptics. “Synaptics is now the only company with TDDI solutions supporting both full in-cell and hybrid in-cell technology, and as we continue to fill out our TDDI portfolio, it is highly gratifying to see our vision of touch and display integration come to fruition.”

Synaptics’ TouchView TDDI portfolio spans resolutions ranging from HD to WQHD and is designed to accelerate the architectural revolution of smartphones. TouchView combines Synaptics’ best-in-class touch controller IP and display driver technology with its proven systems level expertise into a single-chip solution. TDDI delivers lower overall system cost, simplifies the supply chain and enables thinner devices, brighter displays and borderless designs for both full in-cell and hybrid in-cell panel stack-ups.

Synaptics TouchView solutions feature innovative and patented touch controller capabilities, such as support for up to ten fingers, passive stylus, face detection, low-power wake-up gestures, gloved touch, and superior moisture performance. Proprietary display driver features include support for billion color displays, sunlight readability enhancement, and local area auto-contrast adjustment. Image Studio, Synaptics’ unique software development kit, empowers OEMs and LCMs with tools for rapid and custom fine tuning of their displays.

Learn more:

About Synaptics: Synaptics is the pioneer and leader of the human interface revolution, bringing innovative and intuitive user experiences to intelligent devices. Synaptics’ broad portfolio of touch, display, and biometrics products is built on the company’s rich R&D, extensive IP and dependable supply chain capabilities. With solutions designed for mobile, PC and automotive industries, Synaptics combines ease of use, functionality and aesthetics to enable products that help make our digital lives more productive, secure and enjoyable. (NASDAQ: SYNA ) www.synaptics.com .

Join Synaptics on Twitter , LinkedIn , and Facebook , or visit www.synaptics.com .

Synaptics TouchView, Synaptics, and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.

For further information, please contact: David Hurd, Synaptics +1-408-904-2766 david.hurd@synaptics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles